Title |
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A
|
---|---|
Published in |
Patient preference and adherence, June 2015
|
DOI | 10.2147/ppa.s75459 |
Pubmed ID | |
Authors |
Reversa R Mills, Fernando L Pagan |
Abstract |
Cervical dystonia is the most common form of focal dystonia characterized by involuntary muscle contractions causing abnormal movements and posturing of the head and neck and is associated with significant pain. Botulinum toxin is considered first-line therapy in the treatment of pain and abnormal head posturing associated with cervical dystonia. There are currently three botulinum toxin type A neurotoxins and one botulinum type B neurotoxin commercially available and US Food and Drug Administration (FDA) labeled for the treatment of cervical dystonia. This review will focus on the efficacy, safety, and therapeutic use of botulinum type A neurotoxins in the treatment of cervical dystonia. We conclude with a discussion of factors influencing toxin selection including therapeutic effect, duration of effect, side effect profile, cost, and physician preference. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 39 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 13% |
Student > Bachelor | 4 | 10% |
Researcher | 4 | 10% |
Student > Doctoral Student | 2 | 5% |
Other | 2 | 5% |
Other | 5 | 13% |
Unknown | 17 | 44% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 31% |
Nursing and Health Professions | 3 | 8% |
Agricultural and Biological Sciences | 2 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Other | 1 | 3% |
Unknown | 19 | 49% |